11:06 AM EST, 12/19/2024 (MT Newswires) -- Guardant Health ( GH ) and COTA are collaborating to help biopharmaceutical researchers access COTA's electronic health record data and Guardant's clinicogenomic testing data to speed up the development of new cancer treatments, COTA said Thursday.

The partnership expands COTA's data, particularly in lung, breast, and colorectal cancers, creating a larger, more diverse dataset with significant patient overlap to provide better clinical insights, COTA said.

Price: 31.87, Change: -0.50, Percent Change: -1.53